SALT LAKE CITY, May 26, 2020 /PRNewswire/ -- Co-Diagnostics,
Inc. (Nasdaq: CODX), a molecular diagnostics company with a
unique, patented platform for the development of diagnostic tests,
announced today the publication of a paper showing its Logix Smart™
COVID-19 Test Kit was used to demonstrate that the SARS-CoV-2 virus
can be detected in cancer tissue of coronavirus patients, even
before symptoms occur.
The peer-reviewed paper, published in the Journal of Clinical
Pathology, described a study performed at the European Institute of
Oncology in Milan, Italy.
Researchers used the Company's test to determine whether SARS-CoV-2
was present in the removed tumor of a man who later become
symptomatic and was diagnosed with COVID-19.
The tumor, removed from the patient's tongue, was embedded in
formalin-fixed paraffin (a "FFPE" sample) and later tested with the
Company's COVID-19 test kit, along with non-cancer tissue removed
from the patient's salivary glands and lymph nodes. 10 FFPE samples
and six bronchoalveolar samples from other patients without
COVID-19 were also tested.
Co-Diagnostics' test was used by researchers to successfully
identify the COVID-19-causing virus in the coronavirus patient's
FFPE and salivary gland samples and returned negative results on
the lymph node samples, consistent with where the virus is known to
be found. All other samples from all non-COVID-19 patients were
likewise negative. The researchers also describe a recent similar
study in China where that study's
authors were unable to detect the presence of the virus in lung
specimen FFPE samples of COVID-19 positive patients, due to the
lack of a sufficiently robust test.
"We are pleased that the quality of our innovative Logix Smart
COVID-19 test kit has been demonstrated once again by this
impressive and important study," said Dwight Egan, Co-Diagnostics CEO. "Being able to
detect the presence of the virus before symptoms even occur
illustrates the sensitivity and value of our test, especially in
new sample types. The world needs every advantage we can get in our
battle against this deadly disease, and we believe our test has the
attributes needed to benefit millions across the globe."
The CE-marked and FDA EUA Co-Diagnostics Logix Smart COVID-19
test is currently available to all clinical laboratories certified
under Clinical Laboratory Improvement Amendments (CLIA), and is
authorized to be used for the diagnosis of SARS-CoV-2, the virus
that causes COVID-19, in the US and many other countries.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download